25 XP   0   0   10

United Pharm
Buy, Hold or Sell?

Let's analyse United Pharm together

PenkeI guess you are interested in United Pharm. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of United Pharm. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about United Pharm

I send you an email if I find something interesting about United Pharm.

Quick analysis of United Pharm (30 sec.)










What can you expect buying and holding a share of United Pharm? (30 sec.)

How much money do you get?

How much money do you get?
₩0.00
When do you have the money?
1 year
How often do you get paid?
14.8%

What is your share worth?

Current worth
₩25,740.83
Expected worth in 1 year
₩28,515.88
How sure are you?
92.6%

+ What do you gain per year?

Total Gains per Share
₩2,775.05
Return On Investment
12.3%

For what price can you sell your share?

Current Price per Share
₩22,500.00
Expected price per share
₩20,150 - ₩23,000
How sure are you?
50%

1. Valuation of United Pharm (5 min.)




Live pricePrice per Share (EOD)

₩22,500.00

Intrinsic Value Per Share

₩21,151.69 - ₩24,599.75

Total Value Per Share

₩46,892.52 - ₩50,340.58

2. Growth of United Pharm (5 min.)




Is United Pharm growing?

Current yearPrevious yearGrowGrow %
How rich?$265m$229.2m$25.9m10.2%

How much money is United Pharm making?

Current yearPrevious yearGrowGrow %
Making money$8.4m$7.9m$522.6k6.2%
Net Profit Margin17.4%17.6%--

How much money comes from the company's main activities?

3. Financial Health of United Pharm (5 min.)




What can you expect buying and holding a share of United Pharm? (5 min.)

Welcome investor! United Pharm's management wants to use your money to grow the business. In return you get a share of United Pharm.

What can you expect buying and holding a share of United Pharm?

First you should know what it really means to hold a share of United Pharm. And how you can make/lose money.

Speculation

The Price per Share of United Pharm is ₩22,500. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of United Pharm.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in United Pharm, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ₩25,740.83. Based on the TTM, the Book Value Change Per Share is ₩693.76 per quarter. Based on the YOY, the Book Value Change Per Share is ₩676.70 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ₩0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of United Pharm.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 % of Price per Share% of Price per Share% of Price per Share% of Price per Share% of Price per Share
Usd Eps0.120.0%0.570.0%0.540.0%0.430.0%0.370.0%
Usd Book Value Change Per Share0.130.0%0.490.0%0.470.0%0.520.0%0.420.0%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.010.0%
Usd Total Gains Per Share0.130.0%0.490.0%0.470.0%0.520.0%0.430.0%
Usd Price Per Share18.90-17.19-19.72-23.98-20.70-
Price to Earnings Ratio38.34-13.88-1.51-20.51-18.69-
Price-to-Total Gains Ratio142.11-58.77-16.70-90.71-76.36-
Price to Book Ratio1.05-0.99-1.29-1.74-1.69-
Price-to-Total Gains Ratio142.11-58.77-16.70-90.71-76.36-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share15.75
Number of shares63
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.490.52
Usd Total Gains Per Share0.490.52
Gains per Quarter (63 shares)30.5932.80
Gains per Year (63 shares)122.38131.18
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
101221120131121
202452340262252
303673560394383
404904780525514
506126000656645
607347220787776
708578440918907
80979966010491038
9011011088011811169
10012241210013121300

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%26.01.00.096.3%30.01.00.096.8%
Book Value Change Per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%25.02.00.092.6%29.02.00.093.5%
Dividend per Share0.00.04.00.0%0.00.012.00.0%0.00.020.00.0%4.00.023.014.8%7.00.024.022.6%
Total Gains per Share4.00.00.0100.0%11.01.00.091.7%19.01.00.095.0%25.02.00.092.6%29.02.00.093.5%

Fundamentals of United Pharm

About United Pharm

Korea United Pharm Inc. engages in the manufacture and sale of pharmaceutical products in South Korea. It offers products in the areas of respiratory system, musculo-skeletal system, gastro-intestinal tract system, cardiovascular system, anti-cancer, anti-infectives, allergy, immune system, central nervous system, and other diseases, as well OTC drugs. The company also exports its products to approximately 40 countries. Korea United Pharm Inc. was founded in 1987 and is headquartered in Seoul, South Korea.

Fundamental data was last updated by Penke on 2024-04-15 04:09:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is underpriced.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of United Pharm.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit United Pharm earns for each ₩1 of revenue.

  • Above 10% is considered healthy but always compare United Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Net Profit Margin of 3.6% means that ₩0.04 for each ₩1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of United Pharm:

  • The MRQ is 3.6%. The company is making a profit. +1
  • The TTM is 17.4%. The company is making a huge profit. +2
Trends
Current periodCompared to+/- 
MRQ3.6%TTM17.4%-13.7%
TTM17.4%YOY17.6%-0.2%
TTM17.4%5Y14.9%+2.5%
5Y14.9%10Y14.2%+0.7%
1.1.2. Return on Assets

Shows how efficient United Pharm is using its assets to generate profit.

  • Above 5% is considered healthy but always compare United Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.6% Return on Assets means that United Pharm generated ₩0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of United Pharm:

  • The MRQ is 0.6%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 2.6%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ0.6%TTM2.6%-2.1%
TTM2.6%YOY2.7%-0.1%
TTM2.6%5Y2.3%+0.3%
5Y2.3%10Y2.3%+0.0%
1.1.3. Return on Equity

Shows how efficient United Pharm is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare United Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • 0.7% Return on Equity means United Pharm generated ₩0.01 for each ₩1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of United Pharm:

  • The MRQ is 0.7%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 3.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.7%TTM3.3%-2.7%
TTM3.3%YOY3.5%-0.1%
TTM3.3%5Y3.0%+0.4%
5Y3.0%10Y3.0%0.0%

1.2. Operating Efficiency of United Pharm.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient United Pharm is operating .

  • Measures how much profit United Pharm makes for each ₩1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare United Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • An Operating Margin of 0.0% means the company generated ₩0.00  for each ₩1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of United Pharm:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y8.4%-8.4%
5Y8.4%10Y8.4%-0.1%
1.2.2. Operating Ratio

Measures how efficient United Pharm is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • An Operation Ratio of 1.31 means that the operating costs are ₩1.31 for each ₩1 in net sales.

Let's take a look of the Operating Ratio trends of United Pharm:

  • The MRQ is 1.314. The company is inefficient in keeping operating costs low. -1
  • The TTM is 1.231. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ1.314TTM1.231+0.083
TTM1.231YOY1.263-0.031
TTM1.2315Y1.257-0.026
5Y1.25710Y1.175+0.082

1.3. Liquidity of United Pharm.

1.3. Liquidity
1.3.1. Current Ratio

Measures if United Pharm is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A Current Ratio of 3.37 means the company has ₩3.37 in assets for each ₩1 in short-term debts.

Let's take a look of the Current Ratio trends of United Pharm:

  • The MRQ is 3.371. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.195. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.371TTM3.195+0.177
TTM3.195YOY3.341-0.146
TTM3.1955Y3.086+0.108
5Y3.08610Y2.851+0.236
1.3.2. Quick Ratio

Measures if United Pharm is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare United Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Quick Ratio of 2.31 means the company can pay off ₩2.31 for each ₩1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of United Pharm:

  • The MRQ is 2.306. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.233. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.306TTM2.233+0.073
TTM2.233YOY2.175+0.057
TTM2.2335Y1.815+0.418
5Y1.81510Y1.820-0.005

1.4. Solvency of United Pharm.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of United Pharm assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare United Pharm to Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Asset Ratio of 0.19 means that United Pharm assets are financed with 19.2% credit (debt) and the remaining percentage (100% - 19.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of United Pharm:

  • The MRQ is 0.192. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.204. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.192TTM0.204-0.012
TTM0.204YOY0.207-0.002
TTM0.2045Y0.218-0.013
5Y0.21810Y0.228-0.011
1.4.2. Debt to Equity Ratio

Measures if United Pharm is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare United Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A Debt to Equity ratio of 23.8% means that company has ₩0.24 debt for each ₩1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of United Pharm:

  • The MRQ is 0.238. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.257. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.238TTM0.257-0.019
TTM0.257YOY0.261-0.004
TTM0.2575Y0.279-0.021
5Y0.27910Y0.297-0.019

2. Market Valuation of United Pharm

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₩1 in earnings United Pharm generates.

  • Above 15 is considered overpriced but always compare United Pharm to the Drug Manufacturers - Specialty & Generic industry mean.
  • A PE ratio of 38.34 means the investor is paying ₩38.34 for every ₩1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of United Pharm:

  • The EOD is 31.949. Based on the earnings, the company is overpriced. -1
  • The MRQ is 38.339. Based on the earnings, the company is overpriced. -1
  • The TTM is 13.884. Based on the earnings, the company is underpriced. +1
Trends
Current periodCompared to+/- 
EOD31.949MRQ38.339-6.390
MRQ38.339TTM13.884+24.455
TTM13.884YOY1.507+12.377
TTM13.8845Y20.513-6.629
5Y20.51310Y18.687+1.826
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of United Pharm:

  • The EOD is 5.633. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 6.760. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is -2.340. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD5.633MRQ6.760-1.127
MRQ6.760TTM-2.340+9.100
TTM-2.340YOY18.165-20.505
TTM-2.3405Y18.411-20.751
5Y18.41110Y35.151-16.740
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of United Pharm is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Specialty & Generic industry mean).
  • A PB ratio of 1.05 means the investor is paying ₩1.05 for each ₩1 in book value.

Let's take a look of the Price to Book Ratio trends of United Pharm:

  • The EOD is 0.874. Based on the equity, the company is cheap. +2
  • The MRQ is 1.049. Based on the equity, the company is underpriced. +1
  • The TTM is 0.988. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.874MRQ1.049-0.175
MRQ1.049TTM0.988+0.060
TTM0.988YOY1.291-0.302
TTM0.9885Y1.738-0.750
5Y1.73810Y1.689+0.049
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of United Pharm compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--189.998693.762-73%676.703-72%743.675-74%597.283-68%
Book Value Per Share--25740.82824778.888+4%22155.882+16%20254.678+27%17706.850+45%
Current Ratio--3.3713.195+6%3.341+1%3.086+9%2.851+18%
Debt To Asset Ratio--0.1920.204-6%0.207-7%0.218-12%0.228-16%
Debt To Equity Ratio--0.2380.257-7%0.261-9%0.279-15%0.297-20%
Dividend Per Share----0%-0%-0%16.905-100%
Eps--176.059820.147-79%764.596-77%607.511-71%531.387-67%
Free Cash Flow Per Share--998.521313.713+218%670.475+49%446.584+124%371.506+169%
Free Cash Flow To Equity Per Share--998.521313.713+218%670.475+49%446.584+124%372.093+168%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--24599.748--------
Intrinsic Value_10Y_min--21151.687--------
Intrinsic Value_1Y_max--2083.103--------
Intrinsic Value_1Y_min--2045.888--------
Intrinsic Value_3Y_max--6549.983--------
Intrinsic Value_3Y_min--6247.278--------
Intrinsic Value_5Y_max--11367.866--------
Intrinsic Value_5Y_min--10526.303--------
Market Cap331004250000.000-20%397205100000.000361162415000.000+10%416863681762.500-5%507413802767.500-22%440666793901.852-10%
Net Profit Margin--0.0360.174-79%0.176-79%0.149-75%0.142-74%
Operating Margin----0%-0%0.084-100%0.084-100%
Operating Ratio--1.3141.231+7%1.263+4%1.257+5%1.175+12%
Pb Ratio0.874-20%1.0490.988+6%1.291-19%1.738-40%1.689-38%
Pe Ratio31.949-20%38.33913.884+176%1.507+2443%20.513+87%18.687+105%
Price Per Share22500.000-20%27000.00024550.000+10%28175.000-4%34257.500-21%29575.926-9%
Price To Free Cash Flow Ratio5.633-20%6.760-2.340+135%18.165-63%18.411-63%35.151-81%
Price To Total Gains Ratio118.422-20%142.10758.771+142%16.695+751%90.712+57%76.363+86%
Quick Ratio--2.3062.233+3%2.175+6%1.815+27%1.820+27%
Return On Assets--0.0060.026-79%0.027-80%0.023-76%0.023-76%
Return On Equity--0.0070.033-80%0.035-80%0.030-77%0.030-77%
Total Gains Per Share--189.998693.762-73%676.703-72%743.675-74%614.188-69%
Usd Book Value--265076730.975255170758.675+4%229262206.672+16%209720006.530+26%184324854.277+44%
Usd Book Value Change Per Share--0.1330.486-73%0.474-72%0.521-74%0.418-68%
Usd Book Value Per Share--18.01917.345+4%15.509+16%14.178+27%12.395+45%
Usd Dividend Per Share----0%-0%-0%0.012-100%
Usd Eps--0.1230.574-79%0.535-77%0.425-71%0.372-67%
Usd Free Cash Flow--10282682.7883230583.596+218%6925588.885+48%4625007.606+122%3866070.772+166%
Usd Free Cash Flow Per Share--0.6990.220+218%0.469+49%0.313+124%0.260+169%
Usd Free Cash Flow To Equity Per Share--0.6990.220+218%0.469+49%0.313+124%0.260+168%
Usd Market Cap231702975.000-20%278043570.000252813690.500+10%291804577.234-5%355189661.937-22%308466755.731-10%
Usd Price Per Share15.750-20%18.90017.185+10%19.723-4%23.980-21%20.703-9%
Usd Profit--1813043.0788445799.873-79%7923141.434-77%6290016.585-71%5531817.990-67%
Usd Revenue--49697169.41748815076.944+2%45941353.948+8%41991799.838+18%38242601.221+30%
Usd Total Gains Per Share--0.1330.486-73%0.474-72%0.521-74%0.430-69%
 EOD+4 -4MRQTTM+17 -15YOY+17 -155Y+17 -1610Y+17 -18

3.2. Fundamental Score

Let's check the fundamental score of United Pharm based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1531.949
Price to Book Ratio (EOD)Between0-10.874
Net Profit Margin (MRQ)Greater than00.036
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.306
Current Ratio (MRQ)Greater than13.371
Debt to Asset Ratio (MRQ)Less than10.192
Debt to Equity Ratio (MRQ)Less than10.238
Return on Equity (MRQ)Greater than0.150.007
Return on Assets (MRQ)Greater than0.050.006
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of United Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.061
Ma 20Greater thanMa 5023,322.500
Ma 50Greater thanMa 10023,651.000
Ma 100Greater thanMa 20024,426.500
OpenGreater thanClose22,700.000
Total1/5 (20.0%)



Latest Balance Sheet

Balance Sheet of 2023-12-31. Currency in KRW. All numbers in thousands.

Summary
Total Assets468,860,418
Total Liabilities90,179,373
Total Stockholder Equity378,681,044
 As reported
Total Liabilities 90,179,373
Total Stockholder Equity+ 378,681,044
Total Assets = 468,860,418

Assets

Total Assets468,860,418
Total Current Assets244,734,766
Long-term Assets224,125,651
Total Current Assets
Cash And Cash Equivalents 23,913,892
Short-term Investments 127,138,434
Net Receivables 40,267,354
Inventory 49,142,038
Other Current Assets 0
Total Current Assets  (as reported)244,734,766
Total Current Assets  (calculated)240,461,718
+/- 4,273,048
Long-term Assets
Property Plant Equipment 155,278,964
Intangible Assets 9,343,362
Long-term Assets Other 0
Long-term Assets  (as reported)224,125,651
Long-term Assets  (calculated)164,622,326
+/- 59,503,325

Liabilities & Shareholders' Equity

Total Current Liabilities72,594,576
Long-term Liabilities17,584,797
Total Stockholder Equity378,681,044
Total Current Liabilities
Short Long Term Debt 28,437,500
Accounts payable 8,095,548
Other Current Liabilities 2,415,482
Total Current Liabilities  (as reported)72,594,576
Total Current Liabilities  (calculated)38,948,530
+/- 33,646,046
Long-term Liabilities
Long term Debt 10,962,500
Capital Lease Obligations Min Short Term Debt939,032
Long-term Liabilities Other 824,744
Long-term Liabilities  (as reported)17,584,797
Long-term Liabilities  (calculated)12,726,276
+/- 4,858,522
Total Stockholder Equity
Retained Earnings 375,462,907
Total Stockholder Equity (as reported)378,681,044
Total Stockholder Equity (calculated)375,462,907
+/- 3,218,137
Other
Capital Stock8,122,411
Common Stock Shares Outstanding 14,622
Net Debt 15,486,108
Net Invested Capital 418,081,044
Net Working Capital 172,140,190
Property Plant and Equipment Gross 236,289,506



Balance Sheet

Currency in KRW. All numbers in thousands.

 Trend2023-12-312023-09-302023-06-302023-03-312022-12-312022-09-302022-06-302022-03-312021-12-312021-09-302021-06-302021-03-312020-12-312020-09-302020-06-302020-03-312019-12-312019-09-302019-06-302019-03-312015-09-302015-06-302015-03-312014-12-312014-09-302014-06-302014-03-312013-12-312013-09-302013-06-302013-03-31
> Total Assets 
193,470,932
198,100,446
191,588,156
193,539,435
205,690,779
208,282,244
214,962,609
217,100,751
219,490,301
217,498,532
223,903,702
313,394,675
311,452,935
322,092,805
331,243,656
345,618,347
344,246,003
350,320,949
353,433,063
366,409,196
365,730,305
374,362,773
380,032,751
397,481,804
407,786,915
427,914,204
417,890,867
439,919,561
452,730,179
470,914,754
468,860,418
468,860,418470,914,754452,730,179439,919,561417,890,867427,914,204407,786,915397,481,804380,032,751374,362,773365,730,305366,409,196353,433,063350,320,949344,246,003345,618,347331,243,656322,092,805311,452,935313,394,675223,903,702217,498,532219,490,301217,100,751214,962,609208,282,244205,690,779193,539,435191,588,156198,100,446193,470,932
   > Total Current Assets 
0
0
0
0
0
0
0
111,427,276
111,177,535
106,093,502
110,197,471
159,625,880
148,811,599
157,282,622
164,516,968
176,480,456
172,665,046
177,367,608
180,923,771
194,670,977
191,823,378
199,662,867
204,357,480
218,709,234
225,349,947
240,742,454
224,392,334
233,032,550
245,220,680
261,854,513
244,734,766
244,734,766261,854,513245,220,680233,032,550224,392,334240,742,454225,349,947218,709,234204,357,480199,662,867191,823,378194,670,977180,923,771177,367,608172,665,046176,480,456164,516,968157,282,622148,811,599159,625,880110,197,471106,093,502111,177,535111,427,2760000000
       Cash And Cash Equivalents 
0
0
0
0
0
0
0
31,118,484
22,515,206
20,212,596
20,206,448
36,227,215
23,184,806
27,979,012
40,003,890
36,406,471
29,231,136
32,671,463
40,480,544
46,001,437
43,577,444
50,620,762
60,828,754
47,630,990
33,820,027
29,367,717
26,895,879
16,745,188
17,363,972
20,731,776
23,913,892
23,913,89220,731,77617,363,97216,745,18826,895,87929,367,71733,820,02747,630,99060,828,75450,620,76243,577,44446,001,43740,480,54432,671,46329,231,13636,406,47140,003,89027,979,01223,184,80636,227,21520,206,44820,212,59622,515,20631,118,4840000000
       Short-term Investments 
0
0
0
0
0
0
0
11,718,796
19,590,487
16,507,437
17,994,128
31,727,131
38,051,964
41,888,493
38,090,659
49,965,568
53,858,978
52,704,148
53,764,191
59,394,191
60,005,255
62,328,213
62,373,662
81,575,791
100,505,491
118,605,791
115,735,519
120,028,135
131,374,067
134,500,857
127,138,434
127,138,434134,500,857131,374,067120,028,135115,735,519118,605,791100,505,49181,575,79162,373,66262,328,21360,005,25559,394,19153,764,19152,704,14853,858,97849,965,56838,090,65941,888,49338,051,96431,727,13117,994,12816,507,43719,590,48711,718,7960000000
       Net Receivables 
37,256,698
40,249,831
36,683,265
36,344,892
40,268,522
40,670,186
42,013,629
41,129,168
42,707,467
43,197,426
45,587,354
48,358,474
45,331,727
44,482,267
45,421,057
42,107,621
41,276,900
43,810,481
39,223,779
40,336,098
42,542,227
41,686,386
35,811,993
45,133,071
44,977,735
44,652,984
39,104,084
45,026,007
44,346,103
45,831,894
40,267,354
40,267,35445,831,89444,346,10345,026,00739,104,08444,652,98444,977,73545,133,07135,811,99341,686,38642,542,22740,336,09839,223,77943,810,48141,276,90042,107,62145,421,05744,482,26745,331,72748,358,47445,587,35443,197,42642,707,46741,129,16842,013,62940,670,18640,268,52236,344,89236,683,26540,249,83137,256,698
       Other Current Assets 
750,591
1,178,332
2,161,402
499,367
594,838
728,261
654,719
108,695
127,288
219,769
118,977
-1
0
-1
0
1
0
0
-1
0
-1
1
0
0
0
-1
0
0
0
0
0
00000-10001-10-10010-10-1118,977219,769127,288108,695654,719728,261594,838499,3672,161,4021,178,332750,591
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
153,768,795
162,641,336
164,810,183
166,726,688
169,137,892
171,580,956
172,953,341
172,509,292
171,738,219
173,906,927
174,699,906
175,675,271
178,772,570
182,436,968
187,171,750
193,498,532
206,887,011
207,509,498
209,060,241
224,125,651
224,125,651209,060,241207,509,498206,887,011193,498,532187,171,750182,436,968178,772,570175,675,271174,699,906173,906,927171,738,219172,509,292172,953,341171,580,956169,137,892166,726,688164,810,183162,641,336153,768,79500000000000
       Property Plant Equipment 
62,171,617
63,964,580
64,576,791
65,494,251
72,265,276
73,084,714
73,250,465
67,003,054
69,078,393
72,427,946
74,121,029
0
0
0
0
0
0
0
0
0
0
0
0
0
0
130,944,661
136,444,735
138,367,654
138,973,228
140,366,287
155,278,964
155,278,964140,366,287138,973,228138,367,654136,444,735130,944,6610000000000000074,121,02972,427,94669,078,39367,003,05473,250,46573,084,71472,265,27665,494,25164,576,79163,964,58062,171,617
       Goodwill 
0
0
0
0
2,144,013
2,144,013
2,144,013
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000000002,144,0132,144,0132,144,0130000
       Long Term Investments 
0
0
0
0
0
0
0
12,070,560
12,703,289
11,839,168
11,901,694
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0000000000000000000011,901,69411,839,16812,703,28912,070,5600000000
       Intangible Assets 
2,266,100
2,417,447
2,373,639
2,349,208
4,803,424
5,018,995
6,146,286
3,572,004
3,575,347
4,256,809
4,404,770
5,519,937
5,602,403
5,568,457
5,986,613
5,971,475
6,296,428
6,277,146
6,223,154
6,227,920
7,952,623
7,225,698
7,268,159
7,204,435
7,181,468
7,581,313
8,808,071
8,852,066
9,201,713
9,209,474
9,343,362
9,343,3629,209,4749,201,7138,852,0668,808,0717,581,3137,181,4687,204,4357,268,1597,225,6987,952,6236,227,9206,223,1546,277,1466,296,4285,971,4755,986,6135,568,4575,602,4035,519,9374,404,7704,256,8093,575,3473,572,0046,146,2865,018,9954,803,4242,349,2082,373,6392,417,4472,266,100
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
2
0
0
0
169,137,892
0
0
-1
1
0
0
0
0
0
0
0
-1
0
-1
0
0-10-100000001-100169,137,892000200000000000
> Total Liabilities 
57,716,181
59,232,255
50,431,138
52,102,071
58,714,360
55,447,422
56,795,617
55,265,967
58,035,418
51,772,570
53,224,800
80,508,839
72,013,245
73,184,210
76,144,664
83,737,212
77,910,100
75,774,990
76,542,019
85,448,895
78,110,302
75,827,348
79,323,820
90,207,172
86,135,688
84,626,797
80,034,380
95,322,408
93,775,682
95,028,827
90,179,373
90,179,37395,028,82793,775,68295,322,40880,034,38084,626,79786,135,68890,207,17279,323,82075,827,34878,110,30285,448,89576,542,01975,774,99077,910,10083,737,21276,144,66473,184,21072,013,24580,508,83953,224,80051,772,57058,035,41855,265,96756,795,61755,447,42258,714,36052,102,07150,431,13859,232,25557,716,181
   > Total Current Liabilities 
38,597,273
39,003,553
29,985,607
26,659,462
30,693,742
24,819,122
25,910,170
28,425,069
31,895,686
25,976,186
29,402,783
66,295,667
57,436,974
54,484,992
58,699,582
66,949,987
58,209,514
57,308,656
59,790,731
65,696,398
58,930,042
55,468,763
60,854,571
73,355,508
69,012,901
64,880,728
65,880,250
81,212,600
76,455,143
78,626,215
72,594,576
72,594,57678,626,21576,455,14381,212,60065,880,25064,880,72869,012,90173,355,50860,854,57155,468,76358,930,04265,696,39859,790,73157,308,65658,209,51466,949,98758,699,58254,484,99257,436,97466,295,66729,402,78325,976,18631,895,68628,425,06925,910,17024,819,12230,693,74226,659,46229,985,60739,003,55338,597,273
       Short-term Debt 
0
0
0
0
0
0
0
1,708,200
1,654,700
1,601,200
3,462,000
21,635,371
21,186,724
20,863,028
20,666,850
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000020,666,85020,863,02821,186,72421,635,3713,462,0001,601,2001,654,7001,708,2000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
1,708,200
1,654,700
1,601,200
3,462,000
21,476,819
21,186,724
20,863,028
20,666,850
21,389,060
22,445,701
23,357,281
24,353,701
21,677,762
22,818,011
18,714,149
19,900,000
21,380,109
22,053,738
22,426,579
22,000,000
29,000,000
35,000,000
35,000,000
28,437,500
28,437,50035,000,00035,000,00029,000,00022,000,00022,426,57922,053,73821,380,10919,900,00018,714,14922,818,01121,677,76224,353,70123,357,28122,445,70121,389,06020,666,85020,863,02821,186,72421,476,8193,462,0001,601,2001,654,7001,708,2000000000
       Accounts payable 
4,570,081
5,079,751
4,863,696
6,692,843
7,192,644
6,186,424
5,912,063
4,995,018
4,359,308
5,110,773
6,585,372
9,008,463
9,518,016
9,188,729
7,388,566
9,918,242
8,833,825
7,247,327
5,878,527
8,457,731
7,582,514
6,324,038
6,358,974
8,248,987
9,164,407
8,370,475
8,354,403
8,902,250
9,549,410
12,261,308
8,095,548
8,095,54812,261,3089,549,4108,902,2508,354,4038,370,4759,164,4078,248,9876,358,9746,324,0387,582,5148,457,7315,878,5277,247,3278,833,8259,918,2427,388,5669,188,7299,518,0169,008,4636,585,3725,110,7734,359,3084,995,0185,912,0636,186,4247,192,6446,692,8434,863,6965,079,7514,570,081
       Other Current Liabilities 
20,782,438
14,690,828
13,660,582
14,459,697
16,437,645
14,708,938
15,974,396
7,868,220
11,463,243
7,393,967
6,300,461
1
0
1,211,383
1,253,571
0
1,221,947
1,273,922
1,300,271
1,303,275
1,293,609
1,303,307
1,379,305
1,561,969
1,297,150
1,371,713
1,406,108
1,344,619
2,355,579
2,579,190
2,415,482
2,415,4822,579,1902,355,5791,344,6191,406,1081,371,7131,297,1501,561,9691,379,3051,303,3071,293,6091,303,2751,300,2711,273,9221,221,94701,253,5711,211,383016,300,4617,393,96711,463,2437,868,22015,974,39614,708,93816,437,64514,459,69713,660,58214,690,82820,782,438
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
14,213,172
14,576,271
18,699,218
17,445,081
16,787,225
19,700,586
18,466,334
16,751,288
19,752,498
19,180,260
20,358,585
18,469,249
16,851,664
17,122,787
19,746,070
14,154,130
14,109,808
17,320,539
16,402,611
17,584,797
17,584,79716,402,61117,320,53914,109,80814,154,13019,746,07017,122,78716,851,66418,469,24920,358,58519,180,26019,752,49816,751,28818,466,33419,700,58616,787,22517,445,08118,699,21814,576,27114,213,17200000000000
       Capital Lease Obligations Min Short Term Debt
0
0
0
0
0
0
0
-1,708,200
-1,654,700
-1,601,200
-3,462,000
-20,350,656
-19,942,531
-19,659,358
-19,503,702
1,126,163
1,344,576
1,307,572
1,298,814
1,340,793
1,258,696
1,221,235
1,191,134
1,104,812
1,067,951
1,016,072
998,772
981,472
964,171
956,295
939,032
939,032956,295964,171981,472998,7721,016,0721,067,9511,104,8121,191,1341,221,2351,258,6961,340,7931,298,8141,307,5721,344,5761,126,163-19,503,702-19,659,358-19,942,531-20,350,656-3,462,000-1,601,200-1,654,700-1,708,2000000000
       Long-term Liabilities Other 
0
0
0
0
0
0
0
0
0
0
0
-1
0
615,346
599,598
0
590,643
651,870
651,186
710,992
713,438
701,311
749,808
937,600
799,137
868,106
807,860
894,535
870,216
866,942
824,744
824,744866,942870,216894,535807,860868,106799,137937,600749,808701,311713,438710,992651,186651,870590,6430599,598615,3460-100000000000
> Total Stockholder Equity
135,747,898
138,860,820
141,135,023
141,430,096
145,980,046
151,730,686
157,057,784
161,828,186
161,447,963
165,718,430
170,671,781
232,885,834
239,439,690
248,908,595
255,098,992
261,881,135
266,335,903
274,545,958
276,891,044
280,960,301
287,620,003
298,535,425
300,708,932
307,274,632
321,651,228
343,287,406
337,856,486
344,597,153
358,954,497
375,885,927
378,681,044
378,681,044375,885,927358,954,497344,597,153337,856,486343,287,406321,651,228307,274,632300,708,932298,535,425287,620,003280,960,301276,891,044274,545,958266,335,903261,881,135255,098,992248,908,595239,439,690232,885,834170,671,781165,718,430161,447,963161,828,186157,057,784151,730,686145,980,046141,430,096141,135,023138,860,820135,747,898
   Common Stock
7,742,462
7,742,462
7,742,462
7,742,462
7,894,311
8,103,661
8,103,661
8,103,661
8,103,661
8,103,661
8,103,661
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000008,103,6618,103,6618,103,6618,103,6618,103,6618,103,6617,894,3117,742,4627,742,4627,742,4627,742,462
   Retained Earnings 
743,895
821,363
955,674
1,057,386
1,140,120
0
0
136,528,266
139,572,410
143,685,805
148,627,645
222,444,168
228,977,046
237,944,727
244,076,604
250,841,783
255,210,973
263,109,234
265,789,753
273,821,492
280,414,286
291,217,767
293,301,321
299,275,713
313,999,041
337,856,944
333,084,413
341,664,506
356,022,911
372,872,846
375,462,907
375,462,907372,872,846356,022,911341,664,506333,084,413337,856,944313,999,041299,275,713293,301,321291,217,767280,414,286273,821,492265,789,753263,109,234255,210,973250,841,783244,076,604237,944,727228,977,046222,444,168148,627,645143,685,805139,572,410136,528,266001,140,1201,057,386955,674821,363743,895
   Capital Surplus 0000000000000000000000000000000
   Treasury Stock00000000000000000000-5,999,619-5,999,619-5,999,619-2,730,536-2,730,536-2,730,536-2,730,536-2,713,306000
   Other Stockholders Equity 
0
0
0
0
0
0
0
2,207,761
2,054,424
2,213,410
2,225,935
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
000000000000000000002,225,9352,213,4102,054,4242,207,7610000000



Balance Sheet

Currency in KRW. All numbers in thousands.




Cash Flow

Currency in KRW. All numbers in thousands.




Income Statement

Currency in KRW. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue278,943,297
Cost of Revenue-119,965,976
Gross Profit158,977,321158,977,321
 
Operating Income (+$)
Gross Profit158,977,321
Operating Expense-223,669,537
Operating Income55,273,760-64,692,217
 
Operating Expense (+$)
Research Development17,303,588
Selling General Administrative36,754,945
Selling And Marketing Expenses0
Operating Expense223,669,53754,058,533
 
Net Interest Income (+$)
Interest Income6,694,791
Interest Expense-1,619,140
Other Finance Cost-0
Net Interest Income5,075,651
 
Pretax Income (+$)
Operating Income55,273,760
Net Interest Income5,075,651
Other Non-Operating Income Expenses0
Income Before Tax (EBT)60,083,63455,273,760
EBIT - interestExpense = -1,619,140
48,261,714
49,880,854
Interest Expense1,619,140
Earnings Before Interest and Taxes (EBIT)061,702,774
Earnings Before Interest and Taxes (EBITDA)0
 
After tax Income (+$)
Income Before Tax60,083,634
Tax Provision-11,821,920
Net Income From Continuing Ops48,261,71448,261,714
Net Income48,261,714
Net Income Applicable To Common Shares0
 
Non-recurring Events
Discontinued Operations0
Extraordinary Items0
Effect of Accounting Charges0
Other Items0
Non Recurring0
Other Operating Expenses0
Total Other Income/Expenses Net0-5,075,651
 

Technical Analysis of United Pharm
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of United Pharm. The general trend of United Pharm is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine United Pharm's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of United Pharm.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is -1/(-1 +1).

  • Around resistance: The price is trading arround resistance levels. This can be considered as a potential exit level. -1

The bullish price targets are: 22,650 < 22,700 < 23,000.

The bearish price targets are: 21,500 > 20,900 > 20,150.

Tweet this
United Pharm Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of United Pharm. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

United Pharm Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of United Pharm. The current macd is -371.13234012.

The long score for the Moving Average Convergence/Divergence (MACD) is 0/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -4/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the United Pharm price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for United Pharm. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the United Pharm price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending down: The MACD line is trending down. This indicates that the short-term moving average is falling faster than the long-term moving average, suggesting negative momentum in the market. This signals that sellers are becoming more active and insecure, leading to potential price decreases as traders anticipate further losses and are willing to sell at lower prices. -1
United Pharm Daily Moving Average Convergence/Divergence (MACD) ChartUnited Pharm Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of United Pharm. The current adx is 17.93.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell United Pharm shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
United Pharm Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of United Pharm. The current sar is 23,180.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
United Pharm Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of United Pharm. The current rsi is 39.06. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 0/13.
The longshort score for the Relative Strength Index (RSI) is -4/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending down: The RSI is trending down. -1
United Pharm Daily Relative Strength Index (RSI) ChartUnited Pharm Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of United Pharm. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 0/6.
The longshort score for the Stochastic Oscillator is -4/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line < STOCH %D line: The STOCH %K line is below the STOCH %D line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the United Pharm price going down in the near term. -2
  • Trending down: The STOCH %K is trending down. -1
United Pharm Daily Stochastic Oscillator ChartUnited Pharm Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of United Pharm. The current cci is -93.97818872.

United Pharm Daily Commodity Channel Index (CCI) ChartUnited Pharm Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of United Pharm. The current cmo is -24.81371195.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
United Pharm Daily Chande Momentum Oscillator (CMO) ChartUnited Pharm Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of United Pharm. The current willr is -75.47169811.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that United Pharm is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
United Pharm Daily Williams %R ChartUnited Pharm Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of United Pharm.

United Pharm Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of United Pharm. The current atr is 523.82.

United Pharm Daily Average True Range (ATR) ChartUnited Pharm Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of United Pharm. The current obv is -230,256.

United Pharm Daily On-Balance Volume (OBV) ChartUnited Pharm Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of United Pharm. The current mfi is 27.87.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
United Pharm Daily Money Flow Index (MFI) ChartUnited Pharm Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for United Pharm.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-24DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-11-28DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
2023-11-29STOCH LONG EXITThe %K line crosses below the %D line.
2023-11-30MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-04STOCH SHORT EXITThe %K line crosses above the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-07CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-13MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-19STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-12-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2023-12-21STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-12-22DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2023-12-26STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-12-28STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-03STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-04RSI SHORT ENTRY LONG CLOSE70 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-08SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-01-10STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-11STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-15MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-16DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-01-18STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-23DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-29STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-01STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-05STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-08STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-13SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
2024-02-14STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-16SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
STOCH SHORT EXITThe %K line crosses above the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-02-21STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-22CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-26STOCH LONG EXITThe %K line crosses below the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-02-27BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-02-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-02-29MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-06STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-07STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2024-03-08STOCH SHORT EXITThe %K line crosses above the %D line.
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2024-03-11SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-14CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-15STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-19DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-20DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-21CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-22DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-25DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-03-27SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
2024-03-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-29CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-01STOCH SHORT EXITThe %K line crosses above the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
BB SHORT ENTRY LONG CLOSEPrice closed above the lower band.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-03CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-04SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
2024-04-05MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-09STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-11STOCH LONG EXITThe %K line crosses below the %D line.
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-19STOCH LONG EXITThe %K line crosses below the %D line.

6.3. Candlestick Patterns

United Pharm Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of United Pharm based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.061
Ma 20Greater thanMa 5023,322.500
Ma 50Greater thanMa 10023,651.000
Ma 100Greater thanMa 20024,426.500
OpenGreater thanClose22,700.000
Total1/5 (20.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of United Pharm with someone you think should read this too:
  • Are you bullish or bearish on United Pharm? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about United Pharm? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about United Pharm

I send you an email if I find something interesting about United Pharm.


Comments

How you think about this?

Leave a comment

Stay informed about United Pharm.

Receive notifications about United Pharm in your mailbox!